Bisulfite‐free PCDHGB7 methylation in urine enables early noninvasive detection of urothelial carcinoma

IF 6.1 2区医学 Q1 ENGINEERING, BIOMEDICAL

Bioengineering & Translational Medicine Pub Date : 2025-03-11 DOI:10.1002/btm2.70004

Zhicong Yang, Qing Chen, Shihua Dong, Peng Xu, Zhanrui Mao, Yaping Dong, Wei Li, Wenxuan Li, Yang Han, Lihe Dai, Gehong Dong, Yong Zhang, Yinshan Li, Liang Cheng, Weimin Ci, Wenqiang Yu, Chuanliang Xu

{"title":"Bisulfite‐free PCDHGB7 methylation in urine enables early noninvasive detection of urothelial carcinoma","authors":"Zhicong Yang, Qing Chen, Shihua Dong, Peng Xu, Zhanrui Mao, Yaping Dong, Wei Li, Wenxuan Li, Yang Han, Lihe Dai, Gehong Dong, Yong Zhang, Yinshan Li, Liang Cheng, Weimin Ci, Wenqiang Yu, Chuanliang Xu","doi":"10.1002/btm2.70004","DOIUrl":null,"url":null,"abstract":"Urothelial carcinomas (UCs) are the fourth most common male malignancies. However, currently implemented detection methods for UC are usually invasive and/or show passable sensitivity and specificity. An accurate, practical, and effective approach is urgently needed for UC clinical detection. Based on the observation that PCDHGB7 was hypermethylated in UC, we developed a bisulfite‐free quantitative polymerase chain reaction (qPCR)‐based PCDHGB7 evaluation to enable urine for UC noninvasive detection. A total of 887 urine samples from UC/benign diseases of the urinary system (BUD) patients between 2022 and 2023 were included. All collected samples were divided into training and validation sets in a 2:1 ratio based on the order of patient enrollment. Results showed that hypermethylated PCDHGB7 exhibited excellent sensitivity of 87.3% (95% CI: 80.7%–92.3%) and specificity of 91.0% (95% CI: 84.8%–95.3%) in efficiently distinguishing UC from BUD patients in the validation set, which is highly consistent with its performance in the training set. Moreover, PCDHGB7 hypermethylation showed promising potential in identifying sessile UC tumors or cases that might be missed in clinical detection and outperformed standard urine cytology in detecting bladder cancer (82.1% vs. 34.5%), ureter cancer (78.1% vs. 34.4%), and renal pelvis cancer (90.9% vs. 22.7%). Overall, bisulfite‐free qPCR‐based PCDHGB7 evaluation in urine provided a noninvasive, easy‐to‐perform, and effective way for UC early detection.","PeriodicalId":9263,"journal":{"name":"Bioengineering & Translational Medicine","volume":"87 1","pages":""},"PeriodicalIF":6.1000,"publicationDate":"2025-03-11","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Bioengineering & Translational Medicine","FirstCategoryId":"5","ListUrlMain":"https://doi.org/10.1002/btm2.70004","RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"ENGINEERING, BIOMEDICAL","Score":null,"Total":0}

引用次数: 0

Abstract

Urothelial carcinomas (UCs) are the fourth most common male malignancies. However, currently implemented detection methods for UC are usually invasive and/or show passable sensitivity and specificity. An accurate, practical, and effective approach is urgently needed for UC clinical detection. Based on the observation that PCDHGB7 was hypermethylated in UC, we developed a bisulfite‐free quantitative polymerase chain reaction (qPCR)‐based PCDHGB7 evaluation to enable urine for UC noninvasive detection. A total of 887 urine samples from UC/benign diseases of the urinary system (BUD) patients between 2022 and 2023 were included. All collected samples were divided into training and validation sets in a 2:1 ratio based on the order of patient enrollment. Results showed that hypermethylated PCDHGB7 exhibited excellent sensitivity of 87.3% (95% CI: 80.7%–92.3%) and specificity of 91.0% (95% CI: 84.8%–95.3%) in efficiently distinguishing UC from BUD patients in the validation set, which is highly consistent with its performance in the training set. Moreover, PCDHGB7 hypermethylation showed promising potential in identifying sessile UC tumors or cases that might be missed in clinical detection and outperformed standard urine cytology in detecting bladder cancer (82.1% vs. 34.5%), ureter cancer (78.1% vs. 34.4%), and renal pelvis cancer (90.9% vs. 22.7%). Overall, bisulfite‐free qPCR‐based PCDHGB7 evaluation in urine provided a noninvasive, easy‐to‐perform, and effective way for UC early detection.

查看原文本刊更多论文

尿中不含亚硫酸氢盐的PCDHGB7甲基化可以早期无创检测尿路上皮癌

尿路上皮癌（UCs）是第四常见的男性恶性肿瘤。然而，目前实施的UC检测方法通常是侵入性的和/或灵敏度和特异性尚可。迫切需要一种准确、实用、有效的UC临床检测方法。基于对UC中PCDHGB7高甲基化的观察，我们开发了一种基于无亚硫酸盐定量聚合酶链反应（qPCR）的PCDHGB7评估方法，使尿液能够用于UC的无创检测。共纳入了2022年至2023年间UC/泌尿系统良性疾病（BUD）患者的887份尿液样本。所有收集到的样本根据患者入组顺序按2:1的比例分为训练集和验证集。结果显示，高甲基化PCDHGB7在验证集中有效区分UC和BUD患者的敏感性为87.3% (95% CI: 80.7% ~ 92.3%)，特异性为91.0% (95% CI: 84.8% ~ 95.3%)，与训练集中的表现高度一致。此外，PCDHGB7高甲基化在诊断无根性UC肿瘤或可能在临床检测中遗漏的病例方面显示出良好的潜力，并且在检测膀胱癌（82.1%比34.5%）、输尿管癌（78.1%比34.4%）和肾盂癌（90.9%比22.7%）方面优于标准尿细胞学。总体而言，基于无亚硫酸盐qPCR的尿液PCDHGB7评估为UC的早期检测提供了一种无创、易于执行和有效的方法。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Bioengineering & Translational Medicine Pharmacology, Toxicology and Pharmaceutics-Pharmaceutical Science

CiteScore

8.40

自引率

4.10%

发文量

150

审稿时长

12 weeks

期刊介绍： Bioengineering & Translational Medicine, an official, peer-reviewed online open-access journal of the American Institute of Chemical Engineers (AIChE) and the Society for Biological Engineering (SBE), focuses on how chemical and biological engineering approaches drive innovative technologies and solutions that impact clinical practice and commercial healthcare products.